|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
EP2241887B1
(en)
|
2000-11-27 |
2015-01-14 |
Minerva Biotechnologies Corporation |
Diagnostics, drug screening and treatment for cancer
|
|
WO2004035537A2
(en)
|
2002-10-16 |
2004-04-29 |
Euro-Celtique S.A. |
Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
|
|
CA2537263C
(en)
*
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
NZ579482A
(en)
*
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
WO2006081553A2
(en)
|
2005-01-28 |
2006-08-03 |
Ramot At Tel Aviv University, Ltd. |
ANTI-MUC1 α/ß ANTIBODIES
|
|
PL2135881T3
(pl)
|
2005-06-20 |
2012-02-29 |
Genentech Inc |
Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
|
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
WO2007090094A2
(en)
*
|
2006-01-27 |
2007-08-09 |
The University Of Mississippi Medical Center |
Thermally-targeted delivery of medicaments, including doxorubicin
|
|
WO2008054509A2
(en)
*
|
2006-04-14 |
2008-05-08 |
Celsense, Inc. |
Methods for assessing cell labeling
|
|
DK2155248T3
(en)
|
2007-04-12 |
2015-09-14 |
Brigham & Womens Hospital |
Targeting abcb5 for cancer therapy
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
PE20090943A1
(es)
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
EP2176295B1
(en)
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
|
|
DK2644194T3
(en)
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
PT3130923T
(pt)
|
2008-11-14 |
2020-06-17 |
Brigham & Womens Hospital Inc |
Métodos terapêuticos relacionados com células estaminais
|
|
CA3255551A1
(en)
*
|
2010-03-26 |
2025-04-15 |
Memorial Sloan-Kettering Cancer Center |
MUC16 ANTIBODIES AND METHODS OF USE
|
|
AU2014271278B2
(en)
*
|
2010-03-26 |
2017-01-19 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to MUC16 and methods of use thereof
|
|
WO2011133555A2
(en)
|
2010-04-20 |
2011-10-27 |
The Research Foundation Of State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
|
|
US20120148559A1
(en)
|
2010-12-01 |
2012-06-14 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
US9433686B2
(en)
|
2011-01-31 |
2016-09-06 |
The Regents Of The University Of California |
Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
GB201213858D0
(en)
*
|
2012-08-03 |
2012-09-19 |
Mab Design Ltd |
Method
|
|
WO2014028668A2
(en)
*
|
2012-08-14 |
2014-02-20 |
Minerva Biotechnologies Corporation |
Stem cell enhancing therapeutics
|
|
MX338711B
(es)
|
2012-10-12 |
2016-04-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
MX362970B
(es)
|
2013-03-13 |
2019-02-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
BR112015027313A2
(pt)
|
2013-04-29 |
2017-09-26 |
Teva Pharmaceuticals Australia Pty Ltd |
anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
|
|
WO2015116753A1
(en)
*
|
2014-01-29 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
|
|
AU2015243948B2
(en)
|
2014-04-07 |
2020-10-15 |
Minerva Biotechnologies Corporation |
Anti-NME antibody
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
US10544199B2
(en)
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|
|
CN116199790A
(zh)
|
2015-02-10 |
2023-06-02 |
米纳瓦生物技术公司 |
人源化抗MUCl*抗体
|
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
|
SG11201707538XA
(en)
|
2015-03-17 |
2017-10-30 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
MA54884A
(fr)
|
2015-07-01 |
2022-01-12 |
Immatics Biotechnologies Gmbh |
Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
|
|
US11464839B2
(en)
|
2015-12-04 |
2022-10-11 |
Mayo Foundation For Medical Education And Research |
Methods and vaccines for inducing immune responses to multiple different MHC molecules
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
CN105950647A
(zh)
*
|
2016-05-16 |
2016-09-21 |
浙江理工大学 |
一种高效表达与制备外分泌型人源ca125的方法
|
|
JP2019524706A
(ja)
|
2016-07-08 |
2019-09-05 |
ジェネンテック， インコーポレイテッド |
Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
|
|
CN117717604A
(zh)
|
2016-07-19 |
2024-03-19 |
梯瓦制药澳大利亚股份有限公司 |
抗cd47联合治疗
|
|
US10617773B2
(en)
|
2016-08-05 |
2020-04-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US11319380B2
(en)
|
2018-06-04 |
2022-05-03 |
Precigen, Inc. |
MUC16 specific chimeric antigen receptors and uses thereof
|
|
EP3920693A4
(en)
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
EP4161970A4
(en)
|
2020-06-08 |
2024-07-10 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
|
|
CA3183682A1
(en)
|
2020-06-26 |
2021-12-30 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
JP7768775B2
(ja)
*
|
2021-01-14 |
2025-11-12 |
出光興産株式会社 |
ペプチドタグおよびそれを含むタグ付加タンパク質
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|